ArticleDiscover oncology2025
Comprehensive pan-cancer analysis of NLRs family as prognostic and immunity markers based on multi-omics data.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The interplay between recovery and immunity in infectious and non-communicable diseases.Frontiers in cellular and infection microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundMembers of the NOD-like receptors(NLRs)gene family members involved in inflammasome formation have been implicated in cancer initiation, development, progression, angiogenesis, and invasion. This study comprehensively investigated the role of NLRs in cancer through multi-omics analysis, which is of great necessity for a deeper understanding of the pathogenesis of cancer, improvement of cancer prognosis assessment, promotion of drug development, and advancement of precision medicine.
methodsA multi-omics analysis was performed on data from over 10,000 individuals, integrating genomics, epigenomics, transcriptomics, proteomics, and immunogenomics. The dataset encompassed 750 drugs, 33 cancer types, and 24 categories of immune cells. Gene set variation analysis (GSVA) was utilized to ascertain the NLR score, which correlated with survival and cancer pathways. A predictive model was established utilizing univariate Cox and LASSO regression, with subsequent ROC evaluation and nomogram development.
resultsSignificant genomic and epigenetic alterations in NLRs, encompassing copy number variations (CNVs), single nucleotide variations (SNVs), and hyper- methylation, were identified. NLRs expression was connected with immune cell infiltration (ICI) and cancer-related pathways, positively correlating with cytotoxic T cells, NK cells, CD8 T cells, and exhausted T cells, while negatively correlating with neutrophils and naïve T cells. NLR scores were found to be positively correlated with survival outcomes in several cancer types, including LAML, SKCM, SARC, LUAD, KIRP, and COAD. Additionally, a prognostic index for LAML was established based on the strong association between NLR expression and patient outcomes, utilizing a risk model that incorporated ten NLRs derived from GSVA.
conclusionsThis study highlights NLRs as crucial prognostic markers in cancer, with a ten-gene risk model offering independent prognostic value for LAML, laying the groundwork for further exploration of their clinical relevance. NLR alterations and ICI could activate pathways related to cancers. Thus, targeting these NLRs could be a novel approach to treating cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.